Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC trimmed its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 24.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,614 shares of the company’s stock after selling 71,329 shares during the period. Jasper Therapeutics makes up about 3.0% of Ally Bridge Group NY LLC’s holdings, making the stock its 18th biggest holding. Ally Bridge Group NY LLC owned 1.45% of Jasper Therapeutics worth $4,963,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. American Century Companies Inc. raised its holdings in shares of Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares during the period. Virtu Financial LLC acquired a new position in Jasper Therapeutics during the first quarter valued at approximately $306,000. Rhumbline Advisers purchased a new stake in Jasper Therapeutics during the second quarter worth approximately $300,000. Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $599,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Jasper Therapeutics in the 2nd quarter valued at $740,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Performance

Shares of JSPR stock opened at $23.88 on Monday. The company’s 50-day simple moving average is $19.75 and its 200-day simple moving average is $22.69. Jasper Therapeutics, Inc. has a one year low of $4.00 and a one year high of $31.01. The stock has a market capitalization of $359.73 million, a price-to-earnings ratio of -4.24 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.12. As a group, research analysts forecast that Jasper Therapeutics, Inc. will post -4.16 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on JSPR shares. Evercore ISI reiterated an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. BTIG Research assumed coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a “buy” rating and a $90.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Finally, JMP Securities initiated coverage on shares of Jasper Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $70.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $73.00.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.